TVM Capital Life Science Practice Promotes Christoph Schröder, Hui Hsing Ma
TVM Capital has promoted two venture partners for its life science practice to general partner — Christoph Schröder, based in the firm’s Munich headquarters; and Hui Hsing Ma, who works from Singapore and Munich.
Schröder focuses on growth capital investments of family-owned life science businesses in German-speaking countries, and represents TVM Capital on the boards of Biotie Therapies, Probiodrug, and Riemser.
Previously he was a partner at JSB Partners, a life science-focused transatlantic investment banking firm, working with clients that included Probiodrug/OSI, Cardion/Roche, and Tibotec-Virco/Johnson & Johnson. Before JSB, Schröder worked at BASF Pharma, where he served on the executive board based in London; as president of two corporate functions, global production/supply chain, and corporate marketing; as head of strategy/M&A; and as managing director for operations in the UK and Ireland.
Ma represents TVM Capital in the Asian markets. She previously co-led global biotechnology investments at Vertex Management, and made investments in several US and European biotech companies and VC funds. She had also been an advisor to international life science businesses on Asian expansion strategies and fundraising.
Ma has more than 16 years experience in international investment, corporate finance and general management with leading global companies including Singapore Technologies, Banque Nationale de Paris, General Electric, and Morgan Grenfell.
TVM Capital’s life sciences practice has $1.26 billion under management.
Ferrari, Fraser, and Williams To Join Board of Florida’s Institute for the Commercialization of Public Research
Florida Gov. Charlie Crist last week made three appointments to the board of directors of the states’ Institute for the Commercialization of Public Research.
Mario 'Beau' Ferrari, a partner and co-founder of Royal Palm Capital Partners, was appointed for a term beginning Nov. 3, 2008, and ending Oct. 16, 2009.
John Fraser, assistant vice president of research and economic development at Florida State University, was appointed for a term beginning Nov. 3, 2008, and ending Oct. 16, 2010.
Rhys Williams, president of Tequesta BioVentures, was appointed for a term beginning Nov. 3, 2008, and ending Oct. 16, 2011.
The Foundation for the NIH Names Five New Directors
The Foundation for the National Institutes of Health named five new directors this week: Anne Wojcicki, co-founder of 23andMe; Pfizer Chief Medical Officer Joseph Feczko; Peter Neupert, corporate vice president of the Health Solutions Group at Microsoft; Kurt Schmoke, dean of Howard University School of Law; and Samuel Thier, professor emeritus, medicine and health care policy at Harvard Medical School and Massachusetts General Hospital.
The appointments were effective as of Nov. 12, 2008.